Mineralys Therapeutics, Inc.
MLYSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company carries a $2.75B market cap, placing it firmly in the mid-cap category. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Market Cap
$2.75B
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
-12.45
EPS (TTM)
$-4.20
EPS (Fwd)
$-2.50
ROE
-80.9%
ROA
-46.2%
Cash
$661.4M
Total Debt
$97.6M
Free CF
-$203.5M
52W Change
-26.7%
Annual Financials
Cash vs Debt
Where MLYS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MLYS finished 6.18% above its 150-day moving average ($27.35) and 2.39% below its 200-day moving average ($29.75). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MLYS overbought or oversold?
At the September 3, 2026 close, MLYS's RSI(14) was 66.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mineralys Therapeutics, Inc. holds $661.4M in cash against $97.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$203.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -80.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Mineralys Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing MLYS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.